These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 31335281

  • 21. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 22. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M, Lv J, Chu H, Wang J, Chen X, Zhu X, Xue Y, Guan M, Zou H.
    J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
    [Abstract] [Full Text] [Related]

  • 23. Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.
    Aung W, Tsuji AB, Sudo H, Sugyo A, Ukai Y, Kouda K, Kurosawa Y, Furukawa T, Saga T, Higashi T.
    World J Gastroenterol; 2017 Nov 14; 23(42):7551-7562. PubMed ID: 29204055
    [Abstract] [Full Text] [Related]

  • 24. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA, Chang HL, Ong JR, Lee WH, Yeh CT, Tsai JT.
    Cells; 2020 Mar 18; 9(3):. PubMed ID: 32197467
    [Abstract] [Full Text] [Related]

  • 25. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN, Lee SM, Kim JS, Hwang SG.
    Cancer Chemother Pharmacol; 2019 Oct 18; 84(4):809-817. PubMed ID: 31385002
    [Abstract] [Full Text] [Related]

  • 26. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN.
    Oncotarget; 2012 Nov 18; 3(11):1416-27. PubMed ID: 23232026
    [Abstract] [Full Text] [Related]

  • 27. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 18; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 28. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
    Miao X, Liu C, Jiang Y, Wang Y, Kong D, Wu Z, Wang X, Tian R, Yu X, Zhu X, Gong W.
    Cell Death Dis; 2021 Oct 29; 12(11):1020. PubMed ID: 34716294
    [Abstract] [Full Text] [Related]

  • 29. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N, Yen PL, Schwarz MA, Schwarz RE.
    J Cell Biochem; 2012 Mar 29; 113(3):784-91. PubMed ID: 22020918
    [Abstract] [Full Text] [Related]

  • 30. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A.
    Liver Int; 2013 May 29; 33(5):780-93. PubMed ID: 23489999
    [Abstract] [Full Text] [Related]

  • 31. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.
    Anticancer Res; 2012 Jul 29; 32(7):2531-6. PubMed ID: 22753710
    [Abstract] [Full Text] [Related]

  • 32. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.
    J Urol; 2014 Jan 29; 191(1):227-34. PubMed ID: 23954373
    [Abstract] [Full Text] [Related]

  • 33. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
    Chen Y, Zhang L, Yang C, Han J, Wang C, Zheng C, Zhou Y, Lv J, Song Y, Zhu J.
    Bioorg Med Chem; 2016 Mar 01; 24(5):957-66. PubMed ID: 26819001
    [Abstract] [Full Text] [Related]

  • 34. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC, Huang SY, Chang SF, Liao KF, Chiu SC.
    Molecules; 2020 May 25; 25(10):. PubMed ID: 32466169
    [Abstract] [Full Text] [Related]

  • 35. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 May 25; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 36. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 37. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
    Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zörnig M, Zender L, Dombrowski F, Evert M, Schirmacher P, Longerich T.
    Hepatology; 2014 May 15; 59(5):1886-99. PubMed ID: 24285179
    [Abstract] [Full Text] [Related]

  • 38. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 39. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 10; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 40. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X, Gao X, Yang Y, Yang D, Guo Q, Li L, Liu S, Cong W, Lu S, Hou L, Wang B, Li N.
    Apoptosis; 2024 Aug 10; 29(7-8):1161-1184. PubMed ID: 38743191
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.